Catalog Products » Cytokines » TRAIL/Apo2L, Human
Manual
Manual
COAs

TRAIL/Apo2L, Human

TRAIL/Apo2L, also known as Tumor Necrosis Factor Super-Family 10 (TNFSF10), is a pleiotropic cytokine thatbelongs to the TNF superfamily. The full length TRAIL expressed in vivo is a Type II transmembrane protein, although the soluble form also exists and functions. TRAIL has four major receptors: two death receptors DR4 and DR5, two decoy receptors DcR1 and DcR2. TRAIL binds to the death receptors, recruits the FAS-associated death domain, activates caspases 8 and 10, and eventually leads to apoptosis. Because of its antitumor potential, TRAIL is actively studied as a therapeutic agent. On the other hand, abnormal expression of TRAIL in small arteries can induce the proliferation of smooth muscle cells, resulting in increasing vascular remodeling and pulmonary arterial hypertension.
$50.00
Z03124-10

Ask us a question
Product Introduction
Species Human
Protein Construction

Expressed with an N-terminal Met.

TRAIL/Apo2L (Val114-Gly281)
Accession # P50591
Purity > 95% as analyzed by SDS-PAGE
Endotoxin Level < 0.2 EU/μg of protein by gel clotting method
Biological Activity ED50 < 40.0 ng/ml, measured by the cell growth inhibitory assay using RPMI-8226 cells, corresponding to a specific activity of > 2.5 × 104 U/mg.
Expression System E. coli
Apparent Molecular Weight ~19.6 kDa, on SDS-PAGE under reducing conditions.
Formulation Lyophilized after extensive dialysis against PBS.
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O or PBS up to 100 μg/ml.
Storage & Stability Upon receiving, this product remains stable for 6 months at lower than -70°C. Upon reconstitution, the product should be stable for 1 week at 4°C or for 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.
Back

TRAIL/Apo2L, Human

»

TRAIL/Apo2L, Human

»

TRAIL/Apo2L, Human

ED₅₀< 40 ng/mL, measured by the cell growth inhibitory assay using RPMI-8226 cells, corresponding to a specific activity of > 2.5 × 10⁴units/mg. »

<
>

Background
Target Background TRAIL/Apo2L, also known as Tumor Necrosis Factor Super-Family 10 (TNFSF10), is a pleiotropic cytokine thatbelongs to the TNF superfamily. The full length TRAIL expressed in vivo is a Type II transmembrane protein, although the soluble form also exists and functions. TRAIL has four major receptors: two death receptors DR4 and DR5, two decoy receptors DcR1 and DcR2. TRAIL binds to the death receptors, recruits the FAS-associated death domain, activates caspases 8 and 10, and eventually leads to apoptosis. Because of its antitumor potential, TRAIL is actively studied as a therapeutic agent. On the other hand, abnormal expression of TRAIL in small arteries can induce the proliferation of smooth muscle cells, resulting in increasing vascular remodeling and pulmonary arterial hypertension.
Synonyms TNF-related apoptosis-inducing Ligand; TNFSF10; Apo2 Ligand; TL2; CD_antigen: CD253; Protein TRAIL; Apo-2L
Back

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.